Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

BACKGROUND: The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000–500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Antimicrob Chemother
Egile Nagusiak: Nyaku, Amesika N, Zheng, Lu, Gulick, Roy M, Olefsky, Maxine, Berzins, Baiba, Wallis, Carole L, Godfrey, Catherine, Sax, Paul E, Acosta, Edward P, Haas, David W, Smith, Kimberly Y, Sha, Beverly E, Van Dam, Cornelius N, Taiwo, Babafemi O
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477973/
https://ncbi.nlm.nih.gov/pubmed/30668695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky564
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak